Diseases

Rigel Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISSE™ (fostamatinib disodium) in patients with…
Read More...

Selexis SA and TeneoBio announced that they have entered into a service agreement to advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs) targeting…
Read More...

Midatech Pharma announced that it has signed a global licensing agreement with Novartis for the oncology compound panobinostat. Panobinostat will be developed by Midatech for the…
Read More...

Australian researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient’s immune system, to treat an aggressive form of…
Read More...

H. Lundbeck A/S (Lundbeck) has entered into an agreement with biotech company ImmunoBrain Checkpoint, Inc. (IBC) for the rights to IBC's groundbreaking research in the treatment of…
Read More...

A small study by researchers at the National Institutes of Health suggests that mutations in the gene CABLES1 may lead to Cushing syndrome, a rare disorder in which the body…
Read More...

Roche announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC)…
Read More...

Palladio Biosciences announced that it has acquired global rights to lixivaptan from Chiesi USA to  develop it for Polycystic Kidney Disease (PKD), an orphan kidney disease for which…
Read More...

Nektar Therapeutics announced that Takeda signed the research collaboration agreement with Nektar Therapeutics through its wholly-owned subsidiary, Millennium Pharmaceuticals to enter…
Read More...

EMA (European Medicines Agency) has recommended to grant a marketing authorisation in the European Union (EU) for a new ATMP (advanced therapy medicinal product) to treat adult patients…
Read More...

The EMA (European Medicines Agency) has recommended grant for marketing authorisation in the European Union (EU) for Oxervate (cenegermin) to treat neurotrophic keratitis. Oxervate is a…
Read More...

The U.S. FDA has expanded approved use of Vertex Pharmaceuticals manufactured Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations…
Read More...

Cogstate Ltd announced that Eli Lilly’s has selected Cogstate as preferred provider for Alzheimer’s Disease Platform, to support with solutions to ensure high-quality neuropsychological…
Read More...

Dr. Reddy’s Laboratories Ltd. announced that USFDA has approved to launch Doxorubicin Hydrochloride Liposome Injection for intravenous use, in the US market. The approval is an outcome…
Read More...

Vivet Therapeutics announced that it has recieved €37.5 million in a Series A financing round for advancement in developing gene therapies for treatment of rare inherited metabolic…
Read More...

Sandoz Canada announced the launch of Sandoz Olmesartan (olmesartan medoxomil), a generic version of OLMETEC, for the treatment of mild to moderate essential hypertension. This follows…
Read More...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer’s lorlatinib for the treatment of patients with anaplastic lymphoma kinase…
Read More...

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved treatment to…
Read More...

MEDITE Cancer Diagnostics specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis…
Read More...

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who…
Read More...